{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:19:00Z","timestamp":1769044740878,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T00:00:00Z","timestamp":1496102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Increased skin toxicity during combination therapy with a BRAF inhibitor and radiation therapy has recently been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>We present seven melanoma patients with non\u2010resectable stage III or IV disease and concomitant treatment with a BRAF inhibitor and radiation therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all patients, combination therapy yielded a good local response. Only two patients, both on vemurafenib, showed severe radiation dermatitis (CTCAE grade 3\/4) after one and two weeks, respectively, resulting in interruption of BRAF inhibitor treatment. The respective cumulative radiation dose was 10 Gy and 35 Gy. The remaining vemurafenib patients displayed only mild radiation dermatitis CTCAE grade 2; the only dabrafenib patient CTCAE grade 1. In one patient, recall dermatitis was diagnosed 14 days after completion of radiation therapy with a cumulative dose of 30 Gy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Severe skin toxicity caused by BRAF inhibitor\u2010induced radiosensitization is not common and usually amenable to treatment. Thus, combination treatment should remain a therapeutic option, especially in melanoma patients characterized by aggressive tumor growth. Although there is an increased risk of skin toxicity during combination therapy, it is usually well tolerated by most patients. Sequential \u2013 instead of simultaneous \u2013 treatment does not seem to prevent such toxicity reactions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.12672","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T13:56:01Z","timestamp":1496152561000},"page":"703-708","source":"Crossref","is-referenced-by-count":2,"title":["Radiosensitization by BRAF inhibitors"],"prefix":"10.1111","volume":"15","author":[{"given":"Sophia Boyoung","family":"Strobel","sequence":"first","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00adSylvie","family":"P\u00e4tzold","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Frankfurt  Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Cecile","family":"Hassel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"issue":"6","key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ddg.12044","article-title":"Malignant melanoma S3\u2010guideline \u201cdiagnosis, therapy and follow\u2010up of melanoma\u201d","volume":"11","author":"Pflugfelder A","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1610-0387.2012.07942.x","article-title":"Side effects of systemic oncological therapies in dermatology","volume":"10","author":"Zimmer L","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0063-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4265"},{"key":"e_1_2_6_7_1","article-title":"Acute radiation skin toxicity associated with BRAF inhibitors","author":"Pulvirenti T","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4200"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7755"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8473"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4389"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds292"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1113752"},{"issue":"4","key":"e_1_2_6_14_1","first-page":"297","article-title":"Vemurafenib: an \u00adunusual UVA\u2010induced photosensitivity","volume":"22","author":"Gelot P","year":"2013","journal-title":"ExpDermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.12.017"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-014-0707-0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-014-0698-x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000078"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70138-9"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.12672","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.12672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:25:29Z","timestamp":1696242329000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.12672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/ddg.12672"],"URL":"https:\/\/doi.org\/10.1111\/ddg.12672","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]}}}